Search Results - "Mesia R"

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

Authors: Licitra, L. Mesia, R. Rivera, F. et al.

Source: Annals of Oncology. May2011, Vol. 22 Issue 5, p1078-1087. 10p. 1 Color Photograph, 4 Charts, 1 Graph.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors: Vermorken JB Mesia R Rivera F et al.

Source: New England Journal of Medicine. 9/11/2008, Vol. 359 Issue 11, p1116-1127. 12p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.

Authors: Vermorken, J. B. Guigay, J. Mesia, R. et al.

Source: British Journal of Cancer. 5/24/2011, Vol. 104 Issue 11, p1691-1696. 6p. 5 Charts.

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).

Authors: van Herpen, C. M. L. Mauer, M. E. Mesia, R. et al.

Source: British Journal of Cancer. 10/12/2010, Vol. 103 Issue 8, p1173-1181. 9p. 4 Charts, 4 Graphs.

SP-008: Concert Randomised Trials with Panitumumab.

Authors: Giralt, J. Mesia, R. Trigo, J.M. et al.

Source: Radiotherapy & Oncology. Feb2013 Supplement, Vol. 106, pS3-S3. 1p.

Subjects: Therapeutic use of monoclonal antibodies, Cancer radiotherapy, Clinical trials, Oncology, Medical research, Medical publishing

Inhibitory Effect of Cetuximab on Radiation-resistant A431 Cells: An In Vivo Model

Authors: Pueyo, G. Mesia, R. Lozano, A. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Sep2008 Supplement, Vol. 72 Issue s1, pS376-S376. 1p.

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.

Authors: Baro, M de Llobet, L I Figueras, A et al.

Source: British Journal of Cancer. 9/23/2014, Vol. 111 Issue 7, p1310-1318. 9p. 6 Graphs.

The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy.

Authors: Rovira, A Tornero, J Taberna, M et al.

Source: Journal of Laryngology & Otology. Nov2021, Vol. 135 Issue 11, p970-975. 6p.

Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Δ24RGD.

Authors: Majem, M. Cascallo, M. Bayo-Puxan, N. et al.

Source: Cancer Gene Therapy. Jul2006, Vol. 13 Issue 7, p696-705. 10p. 1 Color Photograph, 3 Black and White Photographs, 1 Diagram, 1 Chart, 4 Graphs.

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

Authors: Ferris, R.L. Haddad, R. Even, C. et al.

Source: Annals of Oncology. Jul2020, Vol. 31 Issue 7, p942-950. 9p. 1 Diagram, 2 Charts, 1 Graph.

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.

Authors: Oliva, M Spreafico, A Taberna, M et al.

Source: Annals of Oncology. Jan2019, Vol. 30 Issue 1, p57-67. 11p. 1 Diagram, 2 Charts.

Nutritional changes in patients with locally advanced head and neck cancer during treatment.

Authors: Hurtós, L. Peiró, I. Arribas, L. et al.

Source: Oral Oncology. Aug2017, Vol. 71, p67-74. 8p.

PO-091: TPExtreme randomized trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-P-C in recurrent/metastatic HNSCC.

Authors: Guigay, J. Keilholz, U. Mesia, R. et al.

Source: Radiotherapy & Oncology. Feb2015 Supplement 1, Vol. 114, p46-46. 1p.

Subjects: Head & neck cancer treatment, Docetaxel, Clinical trials, Physiological effects of platinum, Cetuximab, Squamous cell carcinoma, Cancer relapse

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors: Vermorken JB Remenar E van Herpen C et al.

Source: New England Journal of Medicine. 10/25/2007, Vol. 357 Issue 17, p1695-1704. 10p.

URL: 27216293

915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Authors: Greil, R. Rischin, D. Harrington, K.J. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS660-S661. 2p.

1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore).

Authors: Notario Rincon, L. Hierro, C. Esteve, A. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS1105-S1105. 1p.